Trials / Completed
CompletedNCT04203433
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
A Pilot, Open-Label Study in Subjects With Mild-to-Moderate Plaque Psoriasis to Investigate the Dosing Feasibility, Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multi-dose Regimen of DLX105-DMP Administered to a Target Lesion
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- DelArrivo, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DLX105-DMP | 1mg applied to target lesion |
Timeline
- Start date
- 2022-03-21
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2019-12-18
- Last updated
- 2023-05-03
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04203433. Inclusion in this directory is not an endorsement.